Team:Nanjing NFLS/Vision

• Home
• Project
  • Description
  • Background
  • Design
  • Experiment
  • Demonstrate
  • Notebook
  • Vision
• Parts
• Safety

• Model
• Team
  • Team Members
  • Attributions
  • Collaborations
• Human Practices
  • Overview
  • Integrated Human Practices
  • Public Engagement
• Judging

• Home
• Project
  • Description
  • Background
  • Design
  • Experiment
  • Demonstrate
  • Notebook
  • Vision
• Parts
• Safety
• Model
• Team
  • Team Members
  • Attributions
  • Collaborations
• Human Practices
  • Overview
  • Integrated Human Practices
  • Public Engagement
• Judging

Vision

• Vision
• Reference

Vision

In current stage, we have finished the Proof of Concept. As bioethics professor we interviewed in iHP suggested, in the future, we would choose Adeno-Associated Virus Vector instead of Lentivirus Vector to carry the plasmids into human body will prevent the DNA sequence from being integrated into the host cells’ genome, thereby not triggering the controversy towards human gene editing.

Our preliminary results show that by miRNA-ceRNA and tumor-specific promoters, we can exclusively express antigen-derived antigens in tumors, making them artificial antigens for artificial tumors. Artificial tumor neoantigens provide an ideal target for immunotherapy of tumors.

1. In the best case scenario, artificial tumor neoantigens antigens directly activate the body's immune system, producing antigen-specific humoral and cellular immunity, causing tumor regression.

2. When the artificial nascent antigen expressed by the tumor is insufficient to activate the immune system, the HBsAg protein can be used as a vaccine to activate the body against HBsAg humoral and cellular immunity, and exert an anti-tumor effect.

3. For solid tumors that form a tumor-suppressing microenvironment, artificial tumor neonatal antigens can also be used in combination with immunological checkpoint blockers to reverse tumor immunosuppression using immunological checkpoint blockers, while using artificial tumor neonatal antigen activation. The human immune system.

It is worth noting that the system we designed can work in liver cancer cells, but it is not limited to liver cancer cells. We talked with Dr. Zhu and Dr. Ge from Jiangsu CDC about our potential application and they pointed out that CITHA is actually a relatively universal method. By screening different promoters and “Trojan Horses”, we can use this system for different types of cancer treatment. As the figure is shown below, for cancers that have relatively more frequently somatic mutations like cervical cancer or melanoma cancer, the idea of employing “Trojan Horse” will be more effective.

 

Figure 1. The prevalence of somatic mutations across human cancer types ^[1]

 

Reference

[1]Alexandrov LB et al. Signatures ofmutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415-21.doi: 10.1038/nature12477